RxDoctor Payments Data

John Arnold

Family · Marietta, OHNPI 1659894921

Payments from drug & device makers

$3,993in general payments, 2019–2025

Across 145 payments — averaging $27.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$581
  • Novartis$577
  • Amgen$404
  • AstraZeneca$219
  • Pfizer$186
  • plus $703 from 12 others

What the payments were for

  • Travel & lodging$85221%
  • Food & beverage$3,14179%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,993 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$85,567
Medicare patients
736
Services billed
1,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban304$314,544
XareltoRivaroxaban231$243,408
Repatha SureclickEvolocumab190$234,740
JardianceEmpagliflozin28$38,446
Praluent PenAlirocumab35$36,676
BrilintaTicagrelor28$24,787
Repatha PushtronexEvolocumab34$22,444
EntrestoSacubitril/Valsartan17$17,779
LokelmaSodium Zirconium Cyclosilicate12$15,442
Repatha SyringeEvolocumab11$7,885
Metoprolol Succinate576$6,968
Rosuvastatin Calcium365$4,966
Ranolazine ErRanolazine40$4,422
ClopidogrelClopidogrel Bisulfate389$4,026
Isosorbide Dinitrate80$3,375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$186$314,544304 claims
Johnson & JohnsonXarelto$93$243,408231 claims
AstraZenecaBrilinta, Lokelma$219$40,22940 claims
Boehringer IngelheimJardiance$132$38,44628 claims
NovartisEntresto$577$17,77917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.

Other family in Marietta

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →